Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib (Q40593240)

From Wikidata

Jump to navigation Jump to search

scientific article published on 14 May 2013

Language	Label	Description	Also known as
English	Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib	scientific article published on 14 May 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

21 September 2017

Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib (English)

1 reference

Europe PubMed Central

PMC publication ID

21 September 2017

author name string

H A F Stessman

1

1 reference

Europe PubMed Central

PMC publication ID

21 September 2017

A Mansoor

2

1 reference

Europe PubMed Central

PMC publication ID

21 September 2017

F Zhan

3

1 reference

Europe PubMed Central

PMC publication ID

21 September 2017

S Janz

4

1 reference

Europe PubMed Central

PMC publication ID

21 September 2017

M A Linden

5

1 reference

Europe PubMed Central

PMC publication ID

21 September 2017

L B Baughn

6

1 reference

Europe PubMed Central

PMC publication ID

21 September 2017

B Van Ness

7

1 reference

Europe PubMed Central

PMC publication ID

21 September 2017

publication date

14 May 2013

1 reference

Europe PubMed Central

PMC publication ID

21 September 2017

1 reference

Europe PubMed Central

PMC publication ID

21 September 2017

27

1 reference

Europe PubMed Central

PMC publication ID

21 September 2017

10

1 reference

Europe PubMed Central

PMC publication ID

21 September 2017

2075-2077

1 reference

Europe PubMed Central

PMC publication ID

21 September 2017

Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053943

22 September 2017

Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053943

22 September 2017

Factors influencing the abundance of the side population in a human myeloma cell line.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053943

22 September 2017

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053943

22 September 2017

Proteasome inhibitors in the treatment of multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053943

22 September 2017

CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053943

22 September 2017

A transgenic mouse model of plasma cell malignancy shows phenotypic, cytogenetic, and gene expression heterogeneity similar to human multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053943

22 September 2017

Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053943

22 September 2017

Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053943

22 September 2017

Plasma-cell homing

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053943

22 September 2017

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053943

22 September 2017

Three cases of bortezomib-resistant multiple myeloma with extramedullary masses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053943

20 August 2018

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053943

20 August 2018

Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23728080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/LEU.2013.148

1 reference

Europe PubMed Central

PMC publication ID

21 September 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

21 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

21 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40593240&oldid=2203812816"